Download PDF
Thromb Haemost 1979; 41(02): 291-295
DOI: 10.1055/s-0038-1646648
Original Articles
Schattauer GmbH Stuttgart

Factor VIII Inhibitor and Bronchogenic Carcinoma

S A D Al-Ismail
*   The Department of Haematology, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK
,
D H Parry
*   The Department of Haematology, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK
,
C U Moisey
**   The Department of Surgery, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK
,
A L Bloom
*   The Department of Haematology, Welsh National School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF4 4XW, UK
› Author Affiliations
Further Information

Publication History

Received 17 February 1978

Accepted 21 April 1978

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

An inhibitor to procoagulant factor VIII (FVIIIC) developed in a patient three years after palliative resection of a bronchogenic carcinoma. The inhibitor was not active against ristocetin cofactor but possibly had some activity against factor XI. It responded to immunosuppressive therapy. This is apparently the first reported association of carcinoma and factor VIII inhibitor.

 

  • References

  • 1 Biggs R, Bidwell E. 1959; A method for the study of anti-haemophilic globulin inhibitors with reference to six cases. British Journal of Haematology 5: 379
    CrossrefPubMedGoogle Scholar
  • 2 Biggs R, Douglas AJ. 1953; The measurement of prothrombin in plasma. Journal of Clinical Pathology 6: 15
    CrossrefPubMedGoogle Scholar
  • 3 Biggs R. 1976 Human Blood Coagulation, Haemostasis and Thrombosis. 2nd Edition Blackwell
    PubMedGoogle Scholar
  • 4 Bloom AL, Peake IR, Giddings JC. 1973; The presence and reactions of high and lower molecular weight procoagulant factor VIII in the plasma of patients with Von Willebrand’s disease after treatment. Significance for a structural hypothesis for factor VIII Thrombosis Research 3: 389
    CrossrefPubMedGoogle Scholar
  • 5 Feinstein DI, Rapaport SI. 1972; Progress in Hemostasis and Thrombosis. 1: 175
    PubMedGoogle Scholar
  • 6 Garner R, Conning DM. 1970; The assay of factor VII by means of a modified factor VII deficient dog plasma. British Journal of Haematology 18: 57
    CrossrefPubMedGoogle Scholar
  • 7 Giddings JC. 1971; Preparation and the use of a new artificial system for factor XI assay. Medical Laboratory Technology 28: 284
    PubMedGoogle Scholar
  • 8 Hammonds JC, Williams JL, Fox M. 1974; The control of severe bleeding from the bladder by intravesical hyperbaric therapy. British Journal of Urology 46: 309
    CrossrefPubMedGoogle Scholar
  • 9 Handin RI, Martin V, Moloney WC. 1976; Antibody-induced Von Willebrand’s disease: A newly defined inhibitor syndrome. Blood 48: 393
    PubMedGoogle Scholar
  • 10 Hultin MB, London FS, Shapiro SS, Young W. 1977; Heterogeneity of factor VIII antibodies: Further immunochemical and biologic studies. Blood 49: 807
    PubMedGoogle Scholar
  • 11 Ingram GI C, Prentice CR M, Forbes CD, Leslie J. 1973; Low factor VIII-like antigen in acquired Von Willebrand’s syndrome and response to treatment. British Journal of Haematology 25: 137
    CrossrefPubMedGoogle Scholar
  • 12 Kapeller R. 1955; Das Verhalten von factor im serum unter normalen und pathologischen Bedingungen. Zeitschrift für Klinische Medizin 153: 103
    PubMedGoogle Scholar
  • 13 Margolius Jr A, Jackson DP, Ratnoff OD. 1971; Circulating anticoagulants: A study of 40 cases and a review of the literature. Medicine (Baltimore) 40: 145
    PubMedGoogle Scholar
  • 14 Pool Robinson. 1959; Assay of plasma antihaemophilic globulin (AHG). British Journal of Haematology 5: 17
    CrossrefPubMedGoogle Scholar
  • 15 Ratnoff OD, Menzie C. 1951; A new method for the determination of fibrinogen in small samples of plasma. Journal of Laboratory and Clinical Medicine 31: 316
    PubMedGoogle Scholar
  • 16 Stableforth P, Tamagnini GL, Dormandy KM. 1976; Acquired Von Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin-induced platelet aggregation. British Journal of Haematology 33: 565
    CrossrefPubMedGoogle Scholar
  • 17 Wenz B, Friedman G. 1974; Acquired factor VIII inhibitor in a patient with malignant lymphoma. The American Journal of the Medical Sciences 268 (05) 295
    CrossrefPubMedGoogle Scholar